search
Back to results

Study to Investigate the Efficacy of Symbicort® SMART. (SAKURA)

Primary Purpose

Asthma

Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Symbicort Turbuhaler
Terbutaline Turbuhaler
Sponsored by
AstraZeneca
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Asthma focused on measuring Asthma, Symbicort Turbuhaler

Eligibility Criteria

16 Years - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Diagnosis of asthma according to the Global Initiative for Asthma guidelines (GINA) 2007 with a documented history of at least 6 months duration.
  • Reversible airway obstruction, defined as an increase in FEV1 ≥12% relative to baseline for all patients 15-30 minutes after inhalation of in total 2 x 0.4 mg terbutaline Turbuhaler
  • Prescribed use of inhaled glucocorticoid steroid (GCS) (any brand) for at least 12 weeks.

Exclusion Criteria:

  • Respiratory infection affecting the asthma, as judged by the investigator, within 4 weeks.
  • Intake of oral, rectal or parenteral GCS within 4 weeks and/or depot parenteral GCS within 12 weeks.

Sites / Locations

  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site
  • Research Site

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

1

2

Arm Description

Symbicort Turbuhaler 160/4.5 µg one inhalation bid (twice daily) + Symbicort Turbuhaler 160/4.5 µg as needed

Symbicort Turbuhaler 160/4.5 µg one inhalation bid (twice daily) + terbutaline Turbuhaler 0.4 mg as needed

Outcomes

Primary Outcome Measures

The Percentage of Participants Who Had Experienced Asthma Exacerbation(s) at the End of the Study
Asthma exacerbation was defined as deterioration in asthma leading to oral glucocorticosteroid [GCS] treatment, hospitalization, or emergency room [ER] treatment.

Secondary Outcome Measures

Number of Asthma Exacerbations
Asthma exacerbation was defined as deterioration in asthma leading to oral GCS treatment, hospitalization, or ER treatment. Number of asthma exacerbations during 52 weeks treatment was presented here.
Morning Peak Expiratory Flow (PEF)
The mean value from a 52-week treatment period.
Evening PEF
The mean value from a 52-week treatment period.
Forced Expiratory Volume in One Second (FEV1)
The mean value for Weeks 4, 12, 24, 36 and 52 was analysed.
Use of As-needed Medication
The mean value of total daily number of inhalations from the treatment period for use of as-needed medication (daytime, night-time).
Asthma Symptom Score
The mean value from the treatment period for Total Asthma Symptom Score (total score: 0 is best - no asthma symptoms; 6 is worst).
Nights With Awakening(s) Due to Asthma Symptoms
The mean value from the treatment period was presented here.
The Percentage of Participants Who Had Experienced First Mild Asthma Exacerbations
Mild asthma exacerbation was defined as morning PEF ≥20% below baseline, daily as-needed medication use ≥2 inhalations above baseline, or a night with awakening due to asthma symptoms. The percentage of participants who had experienced mild asthma exacerbation(s) at the end of the study was presented here.
Symptom-free Days (no Symptoms and no Awakenings)
A symptom-free day was defined as a day without daytime or night-time symptoms and without night-time awakenings due to asthma symptoms. The mean value was presented here.
Percentage of As-needed-free Days
An as-needed-free day is defined as a night and day with no use of as-needed medication. The mean value from the treatment period was presented here.
Percentage of Asthma-control Days (no Asthma Symptoms, no Awakenings, and no As-needed Use)
An asthma-control day was defined as a a night and day with no asthma symptoms, no awakenings due to asthma symptoms, and no as-needed medication use. The mean value from the treatment period was presented here.
Asthma Control Questionnaire (ACQ)
The ACQ developed by Juniper and colleagues (Juniper et al 1999) was used without the FEV1 and Beta 2-agonist questions. The Asthma Control Questionnaire has 5 questions that are assessed on a 7-point scale from 0 to 6 where 0 represents good control and 6 represents poor control. The overall score is the mean of the five responses. At least 4 out of the 5 questions must have been answered to provide a value. The mean of the overall score for Weeks 4 to 52 was presented here.

Full Information

First Posted
February 4, 2009
Last Updated
November 26, 2012
Sponsor
AstraZeneca
search

1. Study Identification

Unique Protocol Identification Number
NCT00839800
Brief Title
Study to Investigate the Efficacy of Symbicort® SMART.
Acronym
SAKURA
Official Title
A Comparison of Symbicort® SMART (160/4.5μg) and Symbicort® Turbuhaler 160/4.5 μg, Plus Terbutaline Turbuhaler 0.4 mg as Needed, for Treatment of Asthma - a 12-month, Randomized, Double-blind, Parallel Group, Active-controlled, Multinational Phase III Study in Asthmatic Patients From 16 Years
Study Type
Interventional

2. Study Status

Record Verification Date
November 2012
Overall Recruitment Status
Completed
Study Start Date
February 2009 (undefined)
Primary Completion Date
February 2011 (Actual)
Study Completion Date
February 2011 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
AstraZeneca

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The primary objective of this study is to compare the efficacy of Symbicort SMART (Symbicort Turbuhaler 160/4.5μg, one inhalation twice daily plus as needed) with Symbicort Turbuhaler 160/4.5μg, one inhalation twice daily plus terbutaline Turbuhaler 0.4 mg as needed, as asthma therapy

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asthma
Keywords
Asthma, Symbicort Turbuhaler

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
2091 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Experimental
Arm Description
Symbicort Turbuhaler 160/4.5 µg one inhalation bid (twice daily) + Symbicort Turbuhaler 160/4.5 µg as needed
Arm Title
2
Arm Type
Active Comparator
Arm Description
Symbicort Turbuhaler 160/4.5 µg one inhalation bid (twice daily) + terbutaline Turbuhaler 0.4 mg as needed
Intervention Type
Drug
Intervention Name(s)
Symbicort Turbuhaler
Intervention Description
160/4.5 µg
Intervention Type
Drug
Intervention Name(s)
Terbutaline Turbuhaler
Intervention Description
0.4 mg
Primary Outcome Measure Information:
Title
The Percentage of Participants Who Had Experienced Asthma Exacerbation(s) at the End of the Study
Description
Asthma exacerbation was defined as deterioration in asthma leading to oral glucocorticosteroid [GCS] treatment, hospitalization, or emergency room [ER] treatment.
Time Frame
week 52
Secondary Outcome Measure Information:
Title
Number of Asthma Exacerbations
Description
Asthma exacerbation was defined as deterioration in asthma leading to oral GCS treatment, hospitalization, or ER treatment. Number of asthma exacerbations during 52 weeks treatment was presented here.
Time Frame
up to 52 weeks
Title
Morning Peak Expiratory Flow (PEF)
Description
The mean value from a 52-week treatment period.
Time Frame
52-week treatment period
Title
Evening PEF
Description
The mean value from a 52-week treatment period.
Time Frame
2-week run-in period (14 - 18 days before randomization - week 0) and a 52-week treatment period
Title
Forced Expiratory Volume in One Second (FEV1)
Description
The mean value for Weeks 4, 12, 24, 36 and 52 was analysed.
Time Frame
4, 12, 24, 36 and 52 weeks after randomization
Title
Use of As-needed Medication
Description
The mean value of total daily number of inhalations from the treatment period for use of as-needed medication (daytime, night-time).
Time Frame
52-week treatment period
Title
Asthma Symptom Score
Description
The mean value from the treatment period for Total Asthma Symptom Score (total score: 0 is best - no asthma symptoms; 6 is worst).
Time Frame
52-week treatment period
Title
Nights With Awakening(s) Due to Asthma Symptoms
Description
The mean value from the treatment period was presented here.
Time Frame
52-week treatment period
Title
The Percentage of Participants Who Had Experienced First Mild Asthma Exacerbations
Description
Mild asthma exacerbation was defined as morning PEF ≥20% below baseline, daily as-needed medication use ≥2 inhalations above baseline, or a night with awakening due to asthma symptoms. The percentage of participants who had experienced mild asthma exacerbation(s) at the end of the study was presented here.
Time Frame
up to 52 weeks
Title
Symptom-free Days (no Symptoms and no Awakenings)
Description
A symptom-free day was defined as a day without daytime or night-time symptoms and without night-time awakenings due to asthma symptoms. The mean value was presented here.
Time Frame
52-week treatment period
Title
Percentage of As-needed-free Days
Description
An as-needed-free day is defined as a night and day with no use of as-needed medication. The mean value from the treatment period was presented here.
Time Frame
52-week treatment period
Title
Percentage of Asthma-control Days (no Asthma Symptoms, no Awakenings, and no As-needed Use)
Description
An asthma-control day was defined as a a night and day with no asthma symptoms, no awakenings due to asthma symptoms, and no as-needed medication use. The mean value from the treatment period was presented here.
Time Frame
52-week treatment period
Title
Asthma Control Questionnaire (ACQ)
Description
The ACQ developed by Juniper and colleagues (Juniper et al 1999) was used without the FEV1 and Beta 2-agonist questions. The Asthma Control Questionnaire has 5 questions that are assessed on a 7-point scale from 0 to 6 where 0 represents good control and 6 represents poor control. The overall score is the mean of the five responses. At least 4 out of the 5 questions must have been answered to provide a value. The mean of the overall score for Weeks 4 to 52 was presented here.
Time Frame
4, 12, 24, 36 and 52 weeks after randomization

10. Eligibility

Sex
All
Minimum Age & Unit of Time
16 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Diagnosis of asthma according to the Global Initiative for Asthma guidelines (GINA) 2007 with a documented history of at least 6 months duration. Reversible airway obstruction, defined as an increase in FEV1 ≥12% relative to baseline for all patients 15-30 minutes after inhalation of in total 2 x 0.4 mg terbutaline Turbuhaler Prescribed use of inhaled glucocorticoid steroid (GCS) (any brand) for at least 12 weeks. Exclusion Criteria: Respiratory infection affecting the asthma, as judged by the investigator, within 4 weeks. Intake of oral, rectal or parenteral GCS within 4 weeks and/or depot parenteral GCS within 12 weeks.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Tomas Andersson, MD
Organizational Affiliation
AstraZeneca R&D Lund
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Tito Atienza, M.D.
Organizational Affiliation
Mary Mediatrix Medical Center, Lipa City, Philippines
Official's Role
Principal Investigator
Facility Information:
Facility Name
Research Site
City
Capital Federal
State/Province
Buenos Aires
Country
Argentina
Facility Name
Research Site
City
Mar Del Plata
State/Province
Buenos Aires
Country
Argentina
Facility Name
Research Site
City
Monte Grande
State/Province
Buenos Aires
Country
Argentina
Facility Name
Research Site
City
Quilmes
State/Province
Buenos Aires
Country
Argentina
Facility Name
Research Site
City
Rosario
State/Province
Santa Fe
Country
Argentina
Facility Name
Research Site
City
San Miguel de Tucuman
State/Province
Tucuman
Country
Argentina
Facility Name
Research Site
City
Buenos Aires
Country
Argentina
Facility Name
Research Site
City
Ciudad de Buenos Aires
Country
Argentina
Facility Name
Research Site
City
Santa Fe
Country
Argentina
Facility Name
Research Site
City
Porto Alegre
State/Province
Brasil
Country
Brazil
Facility Name
Research Site
City
Belo Horizonte
State/Province
MG
Country
Brazil
Facility Name
Research Site
City
Juiz de Fora
State/Province
MG
Country
Brazil
Facility Name
Research Site
City
Rio de Janeiro
State/Province
RJ
Country
Brazil
Facility Name
Research Site
City
Porto Alegre
State/Province
RS
Country
Brazil
Facility Name
Research Site
City
Florianopolis
State/Province
Santa Catarina
Country
Brazil
Facility Name
Research Site
City
Santo Andre
State/Province
SP
Country
Brazil
Facility Name
Research Site
City
Shenyang
State/Province
Liaoning
Country
China
Facility Name
Research Site
City
Hangzhou
State/Province
Zhejiang
Country
China
Facility Name
Research Site
City
Chongqing
Country
China
Facility Name
Research Site
City
Guang Zhou
Country
China
Facility Name
Research Site
City
Nanjing
Country
China
Facility Name
Research Site
City
Qingdao
Country
China
Facility Name
Research Site
City
Shanghai
Country
China
Facility Name
Research Site
City
Xi An
Country
China
Facility Name
Research Site
City
Tres Rios
State/Province
Cartago
Country
Costa Rica
Facility Name
Research Site
City
Barrio San Bosco
State/Province
San Jose
Country
Costa Rica
Facility Name
Research Site
City
Budapest
Country
Hungary
Facility Name
Research Site
City
Cegled
Country
Hungary
Facility Name
Research Site
City
Debrecen
Country
Hungary
Facility Name
Research Site
City
Deszk
Country
Hungary
Facility Name
Research Site
City
Gyula
Country
Hungary
Facility Name
Research Site
City
Nyiregyhaza
Country
Hungary
Facility Name
Research Site
City
Szazhalombatta
Country
Hungary
Facility Name
Research Site
City
Bangalore
State/Province
Karnataka
Country
India
Facility Name
Research Site
City
Mangalore
State/Province
Karnataka
Country
India
Facility Name
Research Site
City
Mysore
State/Province
Karnataka
Country
India
Facility Name
Research Site
City
Trivandrum
State/Province
Kerala
Country
India
Facility Name
Research Site
City
Mumbai
State/Province
Maharashtra
Country
India
Facility Name
Research Site
City
Nagpur
State/Province
Maharashtra
Country
India
Facility Name
Research Site
City
Pune
State/Province
Maharashtra
Country
India
Facility Name
Research Site
City
Jaipur
State/Province
Rajasthan
Country
India
Facility Name
Research Site
City
Coimabatore
State/Province
Tamilnadu
Country
India
Facility Name
Research Site
City
Noida
Country
India
Facility Name
Research Site
City
Komaki
State/Province
Aichi
Country
Japan
Facility Name
Research Site
City
Seto
State/Province
Aichi
Country
Japan
Facility Name
Research Site
City
Asahi
State/Province
Chiba
Country
Japan
Facility Name
Research Site
City
Matsuyama
State/Province
Ehime
Country
Japan
Facility Name
Research Site
City
Kitakyusyu
State/Province
Fukuoka
Country
Japan
Facility Name
Research Site
City
Yanagawa
State/Province
Fukuoka
Country
Japan
Facility Name
Research Site
City
Isesaki
State/Province
Gunma
Country
Japan
Facility Name
Research Site
City
ORA
State/Province
Gunma
Country
Japan
Facility Name
Research Site
City
Fukuyama
State/Province
Hiroshima
Country
Japan
Facility Name
Research Site
City
Hiroshima-shi
State/Province
Hiroshima
Country
Japan
Facility Name
Research Site
City
Asahikawa
State/Province
Hokkaido
Country
Japan
Facility Name
Research Site
City
Chitose
State/Province
Hokkaido
Country
Japan
Facility Name
Research Site
City
Sapporo
State/Province
Hokkaido
Country
Japan
Facility Name
Research Site
City
Tomakomai
State/Province
Hokkaido
Country
Japan
Facility Name
Research Site
City
AKO
State/Province
Hyogo
Country
Japan
Facility Name
Research Site
City
Himeji
State/Province
Hyogo
Country
Japan
Facility Name
Research Site
City
Kobe-city
State/Province
Hyogo
Country
Japan
Facility Name
Research Site
City
Hitachi
State/Province
Ibaraki
Country
Japan
Facility Name
Research Site
City
Naka-gun
State/Province
Ibaraki
Country
Japan
Facility Name
Research Site
City
Morioka
State/Province
Iwate
Country
Japan
Facility Name
Research Site
City
Sakaide
State/Province
Kagawa
Country
Japan
Facility Name
Research Site
City
Kawasaki-shi
State/Province
Kanagawa
Country
Japan
Facility Name
Research Site
City
Kawasaki
State/Province
Kanagawa
Country
Japan
Facility Name
Research Site
City
Yokohama
State/Province
Kanagawa
Country
Japan
Facility Name
Research Site
City
Sendai
State/Province
Miyagi
Country
Japan
Facility Name
Research Site
City
Nagaoka
State/Province
Niigata
Country
Japan
Facility Name
Research Site
City
Beppu
State/Province
Oita
Country
Japan
Facility Name
Research Site
City
Kurashiki
State/Province
Okayama
Country
Japan
Facility Name
Research Site
City
Sakai
State/Province
Osaka
Country
Japan
Facility Name
Research Site
City
Matsue
State/Province
Shimane
Country
Japan
Facility Name
Research Site
City
Utsunomiya
State/Province
Tochigi
Country
Japan
Facility Name
Research Site
City
Chuo
State/Province
Tokyo
Country
Japan
Facility Name
Research Site
City
Itabashi
State/Province
Tokyo
Country
Japan
Facility Name
Research Site
City
Kodaira
State/Province
Tokyo
Country
Japan
Facility Name
Research Site
City
Kokubunji
State/Province
Tokyo
Country
Japan
Facility Name
Research Site
City
Machida
State/Province
Tokyo
Country
Japan
Facility Name
Research Site
City
Nakano-ku
State/Province
Tokyo
Country
Japan
Facility Name
Research Site
City
Toshima-ku
State/Province
Tokyo
Country
Japan
Facility Name
Research Site
City
Fukuoka
Country
Japan
Facility Name
Research Site
City
Kagoshima
Country
Japan
Facility Name
Research Site
City
Kochi
Country
Japan
Facility Name
Research Site
City
Kyoto
Country
Japan
Facility Name
Research Site
City
Niigata
Country
Japan
Facility Name
Research Site
City
Oita
Country
Japan
Facility Name
Research Site
City
Okayama
Country
Japan
Facility Name
Research Site
City
Bucheon
Country
Korea, Republic of
Facility Name
Research Site
City
Cheongju
Country
Korea, Republic of
Facility Name
Research Site
City
Seoul
Country
Korea, Republic of
Facility Name
Research Site
City
Suwon
Country
Korea, Republic of
Facility Name
Research Site
City
Kubang Kerian
State/Province
Kelantan
Country
Malaysia
Facility Name
Research Site
City
Kuantan
State/Province
Pahang
Country
Malaysia
Facility Name
Research Site
City
Batu Caves
State/Province
Selangor
Country
Malaysia
Facility Name
Research Site
City
Kuala Lumpur
Country
Malaysia
Facility Name
Research Site
City
Penang
Country
Malaysia
Facility Name
Research Site
City
Surco
State/Province
Lima
Country
Peru
Facility Name
Research Site
City
Lima
Country
Peru
Facility Name
Research Site
City
Lipa City
State/Province
Batangas
Country
Philippines
Facility Name
Research Site
City
Davao City
Country
Philippines
Facility Name
Research Site
City
Iloilo City
Country
Philippines
Facility Name
Research Site
City
Manila
Country
Philippines
Facility Name
Research Site
City
Quezon City
Country
Philippines
Facility Name
Research Site
City
Bangkoknoi
State/Province
Bangkok
Country
Thailand
Facility Name
Research Site
City
Naimuang
State/Province
Nakhonratchasima
Country
Thailand
Facility Name
Research Site
City
Hat Yai
State/Province
Songkla
Country
Thailand
Facility Name
Research Site
City
Bangkok
Country
Thailand
Facility Name
Research Site
City
Khon Kaen
Country
Thailand

12. IPD Sharing Statement

Citations:
PubMed Identifier
32718193
Citation
Zhang O, Minku LL, Gonem S. Detecting asthma exacerbations using daily home monitoring and machine learning. J Asthma. 2021 Nov;58(11):1518-1527. doi: 10.1080/02770903.2020.1802746. Epub 2020 Aug 14.
Results Reference
derived

Learn more about this trial

Study to Investigate the Efficacy of Symbicort® SMART.

We'll reach out to this number within 24 hrs